GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
Status:
Terminated
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to investigate:
- the interest of a new monoclonal antibody (GA101)versus rituximab
- the interest of PET to identify early responders
Patients will receive either rituximab (standard treatment), either GA101 (study treatment),
according to the randomization arm.
The monoclonal antibody will be associated to a chemotherapy: CHOP or ACVBP according to
site's choice.A PET scan will be done before inclusion, after 2 chemotherapy cycles, and
after 4 chemotherapy cycles, to identify early patients responders, for who consolidation
with ASCT is not required.